Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Erythrocyte Transfusion | 8 | 2023 | 565 | 1.760 |
Why?
|
Platelet Transfusion | 6 | 2024 | 297 | 1.710 |
Why?
|
Purpura, Thrombotic Thrombocytopenic | 8 | 2020 | 130 | 1.530 |
Why?
|
Blood Banks | 6 | 2023 | 108 | 1.290 |
Why?
|
Blood Group Incompatibility | 4 | 2014 | 136 | 1.060 |
Why?
|
Rh-Hr Blood-Group System | 2 | 2017 | 65 | 1.030 |
Why?
|
Blood Transfusion | 9 | 2023 | 1299 | 1.030 |
Why?
|
Blood Donors | 4 | 2018 | 345 | 0.940 |
Why?
|
Plasma Exchange | 6 | 2020 | 158 | 0.910 |
Why?
|
Fibrinogen | 3 | 2019 | 890 | 0.810 |
Why?
|
Paraproteins | 1 | 2021 | 38 | 0.750 |
Why?
|
Postpartum Hemorrhage | 2 | 2019 | 271 | 0.620 |
Why?
|
Isoantibodies | 6 | 2014 | 674 | 0.610 |
Why?
|
Immunoglobulin A | 1 | 2021 | 980 | 0.570 |
Why?
|
Immunoassay | 1 | 2021 | 746 | 0.570 |
Why?
|
ABO Blood-Group System | 2 | 2017 | 380 | 0.570 |
Why?
|
Leukapheresis | 4 | 2006 | 134 | 0.520 |
Why?
|
Thrombotic Microangiopathies | 4 | 2017 | 123 | 0.490 |
Why?
|
Kell Blood-Group System | 1 | 2014 | 21 | 0.480 |
Why?
|
Blood Grouping and Crossmatching | 5 | 2021 | 100 | 0.460 |
Why?
|
Drug Monitoring | 1 | 2020 | 962 | 0.440 |
Why?
|
Hemorrhage | 6 | 2021 | 3425 | 0.420 |
Why?
|
Blood Loss, Surgical | 3 | 2014 | 636 | 0.420 |
Why?
|
Hemolysis | 5 | 2010 | 424 | 0.410 |
Why?
|
Placenta Accreta | 1 | 2016 | 237 | 0.410 |
Why?
|
Hemolytic-Uremic Syndrome | 1 | 2012 | 106 | 0.400 |
Why?
|
Blood Component Transfusion | 2 | 2021 | 142 | 0.400 |
Why?
|
Multicenter Studies as Topic | 1 | 2017 | 1703 | 0.400 |
Why?
|
Clinical Audit | 1 | 2011 | 29 | 0.380 |
Why?
|
Platelet Count | 5 | 2020 | 782 | 0.380 |
Why?
|
Blood Transfusion, Autologous | 1 | 2011 | 130 | 0.370 |
Why?
|
Blood Safety | 2 | 2023 | 16 | 0.370 |
Why?
|
Thrombocytopenia | 5 | 2024 | 1179 | 0.370 |
Why?
|
Antibodies, Monoclonal, Murine-Derived | 3 | 2012 | 694 | 0.350 |
Why?
|
Multiple Myeloma | 5 | 2023 | 5146 | 0.350 |
Why?
|
Inpatients | 1 | 2020 | 2548 | 0.320 |
Why?
|
Trauma Centers | 1 | 2014 | 937 | 0.320 |
Why?
|
Erythroblastosis, Fetal | 2 | 2022 | 62 | 0.320 |
Why?
|
Erythrocytes | 5 | 2013 | 2419 | 0.310 |
Why?
|
Heparin | 3 | 2017 | 1632 | 0.300 |
Why?
|
Acute Coronary Syndrome | 1 | 2018 | 2190 | 0.250 |
Why?
|
Rho(D) Immune Globulin | 3 | 2022 | 34 | 0.250 |
Why?
|
Patient Selection | 1 | 2017 | 4244 | 0.240 |
Why?
|
Intensive Care Units | 1 | 2018 | 3744 | 0.240 |
Why?
|
Uterine Hemorrhage | 2 | 2016 | 240 | 0.220 |
Why?
|
Sterilization | 2 | 2003 | 133 | 0.210 |
Why?
|
Blood Coagulation Tests | 2 | 2017 | 271 | 0.200 |
Why?
|
Hematologic Diseases | 2 | 2024 | 496 | 0.200 |
Why?
|
Blood Specimen Collection | 3 | 2009 | 238 | 0.200 |
Why?
|
Myocardial Infarction | 2 | 2023 | 11458 | 0.200 |
Why?
|
Cancer Vaccines | 3 | 2016 | 1050 | 0.200 |
Why?
|
Communicable Diseases | 1 | 2010 | 875 | 0.190 |
Why?
|
Humans | 67 | 2024 | 761423 | 0.180 |
Why?
|
Factor VIII | 1 | 2003 | 349 | 0.180 |
Why?
|
Purpura, Thrombocytopenic, Idiopathic | 2 | 2019 | 242 | 0.180 |
Why?
|
Pregnancy Complications | 1 | 2014 | 2947 | 0.180 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2017 | 10203 | 0.180 |
Why?
|
Hematopoietic Stem Cells | 4 | 2008 | 3396 | 0.180 |
Why?
|
Hematopoietic Stem Cell Transplantation | 6 | 2023 | 5670 | 0.170 |
Why?
|
Laboratories | 2 | 2023 | 458 | 0.170 |
Why?
|
Blood Component Removal | 2 | 1997 | 132 | 0.170 |
Why?
|
Anemia | 2 | 2023 | 1508 | 0.160 |
Why?
|
False Positive Reactions | 1 | 2021 | 957 | 0.160 |
Why?
|
Computers | 1 | 2020 | 594 | 0.150 |
Why?
|
Lymphoma, Non-Hodgkin | 3 | 2008 | 1374 | 0.150 |
Why?
|
Plateletpheresis | 2 | 2013 | 38 | 0.150 |
Why?
|
Cryopreservation | 3 | 2016 | 728 | 0.150 |
Why?
|
Middle Aged | 34 | 2024 | 220826 | 0.150 |
Why?
|
Citrates | 1 | 1997 | 135 | 0.140 |
Why?
|
Female | 37 | 2024 | 392581 | 0.140 |
Why?
|
Adult | 29 | 2024 | 221148 | 0.140 |
Why?
|
Partial Thromboplastin Time | 1 | 2017 | 203 | 0.140 |
Why?
|
Retrospective Studies | 15 | 2020 | 80582 | 0.140 |
Why?
|
Transplantation, Autologous | 6 | 2023 | 2116 | 0.130 |
Why?
|
Hypocalcemia | 1 | 1997 | 201 | 0.130 |
Why?
|
Hematocrit | 1 | 2017 | 625 | 0.130 |
Why?
|
National Heart, Lung, and Blood Institute (U.S.) | 1 | 2017 | 322 | 0.130 |
Why?
|
International Normalized Ratio | 1 | 2017 | 382 | 0.130 |
Why?
|
Dendritic Cells | 4 | 2023 | 2746 | 0.120 |
Why?
|
Emergency Service, Hospital | 1 | 2014 | 7874 | 0.120 |
Why?
|
Placenta Previa | 1 | 2016 | 122 | 0.120 |
Why?
|
Blood Platelets | 3 | 2024 | 2481 | 0.120 |
Why?
|
Staphylococcus aureus | 1 | 2003 | 1458 | 0.120 |
Why?
|
Hodgkin Disease | 2 | 2008 | 1378 | 0.120 |
Why?
|
Remission Induction | 3 | 2016 | 2395 | 0.120 |
Why?
|
Male | 33 | 2024 | 360736 | 0.120 |
Why?
|
Blood Preservation | 1 | 2015 | 168 | 0.120 |
Why?
|
ADAM Proteins | 1 | 2015 | 238 | 0.110 |
Why?
|
Anticoagulants | 2 | 2017 | 4813 | 0.110 |
Why?
|
Costs and Cost Analysis | 1 | 2019 | 1668 | 0.110 |
Why?
|
Antifibrinolytic Agents | 1 | 2016 | 292 | 0.110 |
Why?
|
Risk Management | 1 | 2016 | 558 | 0.110 |
Why?
|
Equipment and Supplies, Hospital | 1 | 1992 | 57 | 0.100 |
Why?
|
Metalloendopeptidases | 1 | 2014 | 393 | 0.100 |
Why?
|
Pregnancy | 4 | 2022 | 29862 | 0.100 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 3 | 2017 | 3810 | 0.100 |
Why?
|
Organizational Policy | 1 | 2014 | 432 | 0.100 |
Why?
|
ROC Curve | 1 | 2019 | 3580 | 0.100 |
Why?
|
Aged | 22 | 2024 | 169235 | 0.100 |
Why?
|
Antineoplastic Agents | 3 | 2016 | 13637 | 0.100 |
Why?
|
Clinical Protocols | 1 | 2017 | 1440 | 0.090 |
Why?
|
Hepatitis | 1 | 1993 | 229 | 0.090 |
Why?
|
Granuloma | 1 | 1993 | 327 | 0.090 |
Why?
|
Emergency Medical Services | 1 | 2022 | 1923 | 0.090 |
Why?
|
Unnecessary Procedures | 1 | 2014 | 415 | 0.090 |
Why?
|
Emergencies | 2 | 2014 | 1217 | 0.090 |
Why?
|
BCG Vaccine | 1 | 1993 | 369 | 0.090 |
Why?
|
Immunization | 1 | 2014 | 1227 | 0.090 |
Why?
|
Diagnostic Errors | 1 | 2017 | 1265 | 0.090 |
Why?
|
Immunologic Factors | 1 | 2019 | 1588 | 0.090 |
Why?
|
Cohort Studies | 7 | 2022 | 41446 | 0.080 |
Why?
|
Disease Management | 1 | 2020 | 2507 | 0.080 |
Why?
|
Review Literature as Topic | 1 | 2011 | 347 | 0.080 |
Why?
|
False Negative Reactions | 1 | 2009 | 573 | 0.080 |
Why?
|
Vaccination | 3 | 2016 | 3381 | 0.080 |
Why?
|
Recurrence | 4 | 2023 | 8469 | 0.070 |
Why?
|
Data Collection | 1 | 2017 | 3322 | 0.070 |
Why?
|
Laboratories, Hospital | 1 | 2009 | 192 | 0.070 |
Why?
|
Cesarean Section | 1 | 2016 | 1396 | 0.070 |
Why?
|
Granulocyte Colony-Stimulating Factor | 3 | 2001 | 629 | 0.070 |
Why?
|
Gestational Age | 1 | 2016 | 3576 | 0.070 |
Why?
|
Anemia, Hemolytic, Autoimmune | 1 | 2009 | 147 | 0.070 |
Why?
|
Treatment Outcome | 8 | 2019 | 64651 | 0.070 |
Why?
|
Length of Stay | 3 | 2015 | 6422 | 0.070 |
Why?
|
Bacteremia | 1 | 1993 | 978 | 0.070 |
Why?
|
Antigens, CD34 | 3 | 2001 | 658 | 0.070 |
Why?
|
Hot Temperature | 1 | 1992 | 1440 | 0.070 |
Why?
|
Heparin, Low-Molecular-Weight | 1 | 2008 | 344 | 0.060 |
Why?
|
Medical Order Entry Systems | 1 | 2011 | 521 | 0.060 |
Why?
|
Acute Disease | 3 | 2020 | 7238 | 0.060 |
Why?
|
Lymphoma, B-Cell | 2 | 2003 | 940 | 0.060 |
Why?
|
Antigens, CD1 | 1 | 2008 | 439 | 0.060 |
Why?
|
Splenectomy | 1 | 2007 | 391 | 0.060 |
Why?
|
Autoimmunity | 1 | 2013 | 1355 | 0.060 |
Why?
|
Lymphocyte Transfusion | 1 | 2006 | 232 | 0.060 |
Why?
|
Hemoglobins | 2 | 2023 | 1524 | 0.060 |
Why?
|
Postoperative Care | 1 | 2011 | 1471 | 0.060 |
Why?
|
Factor VII Deficiency | 1 | 2004 | 31 | 0.060 |
Why?
|
Blood Volume | 1 | 2006 | 548 | 0.060 |
Why?
|
Hospitals | 1 | 2018 | 3882 | 0.060 |
Why?
|
Hematoma, Epidural, Cranial | 1 | 2004 | 59 | 0.060 |
Why?
|
Algorithms | 2 | 2018 | 14026 | 0.060 |
Why?
|
Granulocyte-Macrophage Colony-Stimulating Factor | 2 | 2023 | 891 | 0.060 |
Why?
|
Intracranial Hemorrhage, Traumatic | 1 | 2004 | 54 | 0.060 |
Why?
|
Models, Biological | 2 | 2017 | 9469 | 0.060 |
Why?
|
Factor VIIa | 1 | 2004 | 103 | 0.060 |
Why?
|
Guideline Adherence | 1 | 2014 | 2220 | 0.060 |
Why?
|
Lymphocyte Count | 1 | 2006 | 778 | 0.060 |
Why?
|
Afibrinogenemia | 1 | 2003 | 18 | 0.060 |
Why?
|
Complement System Proteins | 1 | 2007 | 788 | 0.050 |
Why?
|
Membrane Glycoproteins | 1 | 2014 | 3702 | 0.050 |
Why?
|
Blood Transfusion, Intrauterine | 1 | 2022 | 28 | 0.050 |
Why?
|
Fibrin Tissue Adhesive | 1 | 2003 | 86 | 0.050 |
Why?
|
Exchange Transfusion, Whole Blood | 1 | 2022 | 59 | 0.050 |
Why?
|
Th1 Cells | 1 | 2008 | 1037 | 0.050 |
Why?
|
Parasitic Diseases | 1 | 2002 | 76 | 0.050 |
Why?
|
Uremia | 1 | 2003 | 201 | 0.050 |
Why?
|
Aged, 80 and over | 5 | 2014 | 58956 | 0.050 |
Why?
|
Creutzfeldt-Jakob Syndrome | 1 | 2002 | 93 | 0.050 |
Why?
|
Platelet Factor 4 | 2 | 2017 | 129 | 0.050 |
Why?
|
Wounds and Injuries | 1 | 2014 | 2491 | 0.050 |
Why?
|
Medical Audit | 1 | 2003 | 453 | 0.050 |
Why?
|
Case-Control Studies | 1 | 2019 | 22168 | 0.050 |
Why?
|
Anemia, Hemolytic | 1 | 2002 | 163 | 0.050 |
Why?
|
Boston | 1 | 2014 | 9330 | 0.050 |
Why?
|
Research Design | 1 | 2017 | 6178 | 0.050 |
Why?
|
Peripheral Blood Stem Cell Transplantation | 1 | 2003 | 263 | 0.050 |
Why?
|
Infant, Newborn | 3 | 2022 | 26212 | 0.050 |
Why?
|
Echocardiography, Doppler, Color | 1 | 2002 | 352 | 0.050 |
Why?
|
Coronary Artery Bypass | 2 | 2008 | 2189 | 0.050 |
Why?
|
Chimera | 1 | 2002 | 453 | 0.050 |
Why?
|
Blood Cells | 1 | 2003 | 305 | 0.050 |
Why?
|
Arthroplasty, Replacement, Knee | 1 | 2011 | 1385 | 0.050 |
Why?
|
Quality Control | 1 | 2023 | 832 | 0.050 |
Why?
|
Leukemia, Myeloid, Acute | 1 | 2016 | 3613 | 0.050 |
Why?
|
Urinary Bladder Neoplasms | 1 | 1993 | 2223 | 0.050 |
Why?
|
Hospital Mortality | 1 | 2014 | 5291 | 0.040 |
Why?
|
Risk Factors | 4 | 2016 | 74167 | 0.040 |
Why?
|
Acute Lung Injury | 1 | 2024 | 367 | 0.040 |
Why?
|
Young Adult | 3 | 2017 | 59207 | 0.040 |
Why?
|
Tuberculosis | 1 | 1993 | 2016 | 0.040 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 4 | 2023 | 11740 | 0.040 |
Why?
|
Cardiac Surgical Procedures | 1 | 2015 | 3630 | 0.040 |
Why?
|
Mycoses | 1 | 2002 | 386 | 0.040 |
Why?
|
Colony-Forming Units Assay | 2 | 1997 | 352 | 0.040 |
Why?
|
Killer Cells, Natural | 1 | 2008 | 2203 | 0.040 |
Why?
|
Stem Cell Transplantation | 2 | 2008 | 1600 | 0.040 |
Why?
|
Immunotherapy | 2 | 2013 | 4650 | 0.040 |
Why?
|
Proportional Hazards Models | 3 | 2019 | 12456 | 0.040 |
Why?
|
Photosensitizing Agents | 1 | 2022 | 623 | 0.040 |
Why?
|
Decision Making | 1 | 2011 | 3929 | 0.040 |
Why?
|
Massachusetts | 2 | 2023 | 8832 | 0.040 |
Why?
|
Recombinant Proteins | 2 | 2004 | 6532 | 0.040 |
Why?
|
Tissue Plasminogen Activator | 1 | 2003 | 1164 | 0.040 |
Why?
|
Catheterization | 1 | 2003 | 1432 | 0.040 |
Why?
|
Prevalence | 1 | 2014 | 15717 | 0.040 |
Why?
|
Tissue Donors | 1 | 2006 | 2331 | 0.030 |
Why?
|
Virus Diseases | 1 | 2002 | 719 | 0.030 |
Why?
|
Dexamethasone | 1 | 2023 | 1947 | 0.030 |
Why?
|
Antibodies | 1 | 2023 | 2421 | 0.030 |
Why?
|
Fetus | 1 | 2022 | 1864 | 0.030 |
Why?
|
Cell Culture Techniques | 1 | 2003 | 1667 | 0.030 |
Why?
|
Equipment Failure | 1 | 1997 | 578 | 0.030 |
Why?
|
Early Diagnosis | 1 | 2020 | 1186 | 0.030 |
Why?
|
Mortality | 2 | 2017 | 2900 | 0.030 |
Why?
|
Warfarin | 1 | 2003 | 1483 | 0.030 |
Why?
|
Bacterial Infections | 1 | 2002 | 1393 | 0.030 |
Why?
|
Intention to Treat Analysis | 1 | 2015 | 413 | 0.030 |
Why?
|
Granulocytes | 1 | 1995 | 552 | 0.030 |
Why?
|
Administration, Intravesical | 1 | 1993 | 92 | 0.030 |
Why?
|
Disease-Free Survival | 2 | 2019 | 6814 | 0.030 |
Why?
|
Cyclophosphamide | 2 | 1997 | 2218 | 0.030 |
Why?
|
Physicians | 1 | 2011 | 4591 | 0.030 |
Why?
|
Mitral Valve Insufficiency | 1 | 2002 | 1404 | 0.030 |
Why?
|
Multiple Organ Failure | 1 | 2015 | 387 | 0.030 |
Why?
|
Adolescent | 3 | 2017 | 88313 | 0.030 |
Why?
|
Mitoxantrone | 2 | 2003 | 148 | 0.020 |
Why?
|
Ifosfamide | 2 | 2003 | 232 | 0.020 |
Why?
|
Neoplasm, Residual | 1 | 2016 | 1008 | 0.020 |
Why?
|
Leukocyte Count | 1 | 1995 | 1596 | 0.020 |
Why?
|
Immune System | 1 | 2016 | 795 | 0.020 |
Why?
|
Incidence | 1 | 2009 | 21341 | 0.020 |
Why?
|
Thrombosis | 1 | 2004 | 2942 | 0.020 |
Why?
|
Etoposide | 2 | 2003 | 634 | 0.020 |
Why?
|
Cell Separation | 2 | 2008 | 1721 | 0.020 |
Why?
|
Evaluation Studies as Topic | 1 | 1992 | 1626 | 0.020 |
Why?
|
Cell Fusion | 1 | 2010 | 294 | 0.020 |
Why?
|
Leukocytes, Mononuclear | 1 | 1997 | 1843 | 0.020 |
Why?
|
Antibodies, Protozoan | 1 | 2010 | 252 | 0.020 |
Why?
|
United States | 1 | 2017 | 72339 | 0.020 |
Why?
|
Antigens, Neoplasm | 1 | 2016 | 1994 | 0.020 |
Why?
|
Kaplan-Meier Estimate | 1 | 2019 | 6479 | 0.020 |
Why?
|
Propensity Score | 1 | 2016 | 1908 | 0.020 |
Why?
|
Antigens, Protozoan | 1 | 2010 | 316 | 0.020 |
Why?
|
Autoantibodies | 1 | 2017 | 2124 | 0.020 |
Why?
|
Severity of Illness Index | 2 | 2017 | 15838 | 0.020 |
Why?
|
Bone Marrow Transplantation | 1 | 1995 | 2695 | 0.020 |
Why?
|
Kidney Neoplasms | 1 | 2004 | 4248 | 0.020 |
Why?
|
Liver Neoplasms | 1 | 2003 | 4320 | 0.020 |
Why?
|
Antigens, CD1d | 1 | 2008 | 228 | 0.020 |
Why?
|
Hemostasis | 1 | 2010 | 467 | 0.020 |
Why?
|
Immunity, Cellular | 1 | 2013 | 1560 | 0.020 |
Why?
|
Prospective Studies | 2 | 2024 | 54415 | 0.020 |
Why?
|
Delivery of Health Care | 1 | 2023 | 5335 | 0.020 |
Why?
|
Blood Group Antigens | 1 | 2007 | 186 | 0.020 |
Why?
|
Reproducibility of Results | 1 | 2023 | 20093 | 0.020 |
Why?
|
Subarachnoid Hemorrhage, Traumatic | 1 | 2004 | 13 | 0.020 |
Why?
|
Prothrombin Time | 1 | 2004 | 117 | 0.010 |
Why?
|
Hybrid Cells | 1 | 2004 | 422 | 0.010 |
Why?
|
T-Lymphocytes | 2 | 2016 | 10194 | 0.010 |
Why?
|
Hematoma, Subdural | 1 | 2004 | 127 | 0.010 |
Why?
|
Laminectomy | 1 | 2004 | 225 | 0.010 |
Why?
|
T-Lymphocytes, Regulatory | 1 | 2016 | 3077 | 0.010 |
Why?
|
Immunophenotyping | 1 | 2008 | 1870 | 0.010 |
Why?
|
Hemorheology | 1 | 2002 | 144 | 0.010 |
Why?
|
Thrombin | 1 | 2004 | 590 | 0.010 |
Why?
|
Erythrocytes, Abnormal | 1 | 2002 | 121 | 0.010 |
Why?
|
Antigens | 1 | 2007 | 1446 | 0.010 |
Why?
|
Filgrastim | 1 | 2001 | 132 | 0.010 |
Why?
|
Survival Rate | 2 | 2008 | 12720 | 0.010 |
Why?
|
Macrophages | 1 | 1995 | 5768 | 0.010 |
Why?
|
Histocompatibility Testing | 1 | 2002 | 719 | 0.010 |
Why?
|
Coculture Techniques | 1 | 2004 | 1340 | 0.010 |
Why?
|
Hematopoietic Stem Cell Mobilization | 1 | 2001 | 225 | 0.010 |
Why?
|
Central Nervous System Diseases | 1 | 2004 | 520 | 0.010 |
Why?
|
Microsatellite Repeats | 1 | 2002 | 785 | 0.010 |
Why?
|
Time Factors | 2 | 2015 | 39975 | 0.010 |
Why?
|
Germ Cells | 1 | 2002 | 634 | 0.010 |
Why?
|
CD4-Positive T-Lymphocytes | 1 | 2010 | 4370 | 0.010 |
Why?
|
Stress, Mechanical | 1 | 2002 | 1674 | 0.010 |
Why?
|
Confidence Intervals | 1 | 2003 | 2927 | 0.010 |
Why?
|
Breast Neoplasms | 1 | 2004 | 21012 | 0.010 |
Why?
|
CD8-Positive T-Lymphocytes | 1 | 2010 | 4575 | 0.010 |
Why?
|
Acinetobacter Infections | 1 | 1997 | 73 | 0.010 |
Why?
|
Tumor Cells, Cultured | 1 | 2004 | 6132 | 0.010 |
Why?
|
Prognosis | 1 | 2017 | 29620 | 0.010 |
Why?
|
Drug Contamination | 1 | 1997 | 152 | 0.010 |
Why?
|
Blood Cell Count | 1 | 1997 | 397 | 0.010 |
Why?
|
Interferon-gamma | 1 | 2004 | 3159 | 0.010 |
Why?
|
Nitrogen | 1 | 1997 | 348 | 0.010 |
Why?
|
Haplotypes | 1 | 2002 | 2775 | 0.010 |
Why?
|
Antibodies, Monoclonal | 2 | 2003 | 9179 | 0.010 |
Why?
|
Pedigree | 1 | 2002 | 4589 | 0.010 |
Why?
|
Flow Cytometry | 1 | 2004 | 5868 | 0.010 |
Why?
|
Risk | 1 | 2004 | 9612 | 0.010 |
Why?
|
Mothers | 1 | 2002 | 2192 | 0.010 |
Why?
|
Reference Values | 1 | 1998 | 4921 | 0.010 |
Why?
|
Postoperative Complications | 2 | 2004 | 15650 | 0.010 |
Why?
|
Immunohistochemistry | 1 | 2004 | 11073 | 0.010 |
Why?
|
Bone Marrow Cells | 1 | 1997 | 2415 | 0.010 |
Why?
|
Cell Proliferation | 1 | 2004 | 10441 | 0.000 |
Why?
|
Infant | 1 | 2010 | 36205 | 0.000 |
Why?
|
Child, Preschool | 1 | 2010 | 42254 | 0.000 |
Why?
|
Child | 1 | 2010 | 80162 | 0.000 |
Why?
|
Neoplasms | 1 | 2010 | 22164 | 0.000 |
Why?
|